Indication
Prostate Adenocarcinoma
38 clinical trials
35 products
18 drugs
Product
HistrelinClinical trial
Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate CancerStatus: Completed, Estimated PCD: 2003-08-01
Clinical trial
Phase III, Open-Label Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Metastatic Prostate CancerStatus: Completed, Estimated PCD: 2001-12-01
Product
ZoladexProduct
ORCA-010Clinical trial
A Phase I/IIa Study Evaluating the Safety and Tolerability of Intratumoral Administration of ORCA-010 in Treatment-Naïve Patients With Localized Prostate Cancer.Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
sipuleucel-TClinical trial
Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
NivolumabProduct
DegarelixProduct
BMS-986253Clinical trial
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2017-07-10
Product
EnzalutamideDrug
LHRH agonistProduct
LeuprolideClinical trial
A Phase 1b Study of Adaptive Androgen Deprivation Therapy for State IV Castration Sensitive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2022-06-22
Product
AbirateroneProduct
PrednisoneClinical trial
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-03-14
Product
CediranibProduct
OlaparibClinical trial
Multimodal PET/MRI Machine Learning Approaches for Characterization of Solid TumorsStatus: Recruiting, Estimated PCD: 2024-08-31
Product
[18F]DCFPyLClinical trial
Study of Stereotactic Body Radiotherapy (SBRT) for High-Risk Localized Prostrate CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-27
Clinical trial
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
ApalutamideClinical trial
Phase II Randomized Study of Docetaxel With or Without Thalidomide in Patients With Androgen-Independent Metastatic Prostate CancerStatus: Completed
Drug
docetaxelDrug
thalidomideClinical trial
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide TreatmentStatus: Active (not recruiting), Estimated PCD: 2019-10-01
Clinical trial
Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate CancerStatus: Recruiting, Estimated PCD: 2024-01-20
Product
ARN-509Clinical trial
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate CancerStatus: Recruiting, Estimated PCD: 2024-10-31
Product
Antiandrogen TherapyDrug
DocetaxelClinical trial
Prospective Study of Stereotactic Body Radiotherapy (SBRT) Following Radical ProstatectomyStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET ImagingStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
CabazitaxelClinical trial
Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the ProstateStatus: Terminated
Product
AlendronateProduct
ketoconazoleClinical trial
A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After ProstatectomyStatus: Active (not recruiting), Estimated PCD: 2022-03-01
Clinical trial
Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2011-03-16
Product
BicalutamideProduct
GoserelinClinical trial
PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyStatus: Active (not recruiting), Estimated PCD: 2025-05-15
Drug
AN0025Product
RucaparibClinical trial
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)Status: Completed, Estimated PCD: 2023-03-15
Product
ESK981Clinical trial
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Product
IpilimumabDrug
R-CHOPClinical trial
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the ProstateStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Androgen Deprivation TherapyClinical trial
Pre-Surgical Androgen Deprivation Therapy With or Without Axitinib in Previously Untreated Prostate Cancer Patients With Known or Suspected Lymph Node MetastasisStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
AxitinibClinical trial
68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate CancerStatus: Completed, Estimated PCD: 2021-12-19
Clinical trial
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2018-11-02
Drug
enzalutamideDrug
abirateroneDrug
prednisoneClinical trial
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical ProstatectomyStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase I/II Clinical Trial of Lenalidomide in Combination With Oral Cyclophosphamide in Patients With Previously Treated Hormone Refractory Prostate CancerStatus: Terminated, Estimated PCD: 2015-05-19
Drug
lenalidomideDrug
cyclophosphamideClinical trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 TrialStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2019-04-10
Drug
enzalutamideDrug
degarelixClinical trial
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
T-VECClinical trial
Intra-operative Optical Imaging Utilizing Anti-PSMA (Prostate Specific Membrane Antigen) Fluorescent Antibody During Robotic Assisted Laparoscopic ProstatectomyStatus: Completed, Estimated PCD: 2018-05-10
Product
MDX1201Clinical trial
A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)Status: Active (not recruiting), Estimated PCD: 2020-12-01
Clinical trial
A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic CancerStatus: Completed, Estimated PCD: 2018-05-01
Product
Sodium SeleniteClinical trial
Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate CancerStatus: Completed, Estimated PCD: 2021-01-20
Product
HER2BiDrug
mFOLFOX6Clinical trial
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active SurveillanceStatus: Completed, Estimated PCD: 2018-11-30
Product
Rilimogene Galvacirepvec